e-Drug3D

2018

VERICIGUAT

INN
VERICIGUAT

cas 1350653-20-1

CLASS

CARDIOVASCULAR
GUANYLATE CYCLASE (SGC) STIMULATOR
REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF)

ROUTE (list)

ORAL

ATC code

C01DX22

PK parameters

F 93 PERCENT
Tmax 1 HOUR
VD 44 LITER
Cl 1.6 LITER / HOUR
PPB 98 PERCENT
t1/2 30 HOUR

Target

DrugCentral

Guanylate cyclase soluble subunit beta-1 UNIPROT Q02153 GUCY1B3

Download SDF file

Carbamic acid, N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-, methyl ester

Formula:
C19H16F2N8O2

Calculated chemical properties:

MW 426.40
NB_atoms 31
XLogP 2.56
PSA 129.918
NB_HD 5
NB_HA 10
fsp3 0.11
Lipinski(0=no;1=yes) 1

FDA
NDA 214377 (label) INN (VERICIGUAT) VERQUVO (MSD) APPROVAL= AP YEAR= 2021
NDA 220221 (pdf not found) INN (VERICIGUAT) VERICIGUAT (TORRENT PHARMACEUTICALS LTD) APPROVAL= TA YEAR= 2026
NDA 220264 (pdf not found) INN (VERICIGUAT) VERICIGUAT (CHANGZHOU PHARMACEUTICAL FACTORY) APPROVAL= TA YEAR= 2026